Opus Genetics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · North Carolina, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8 Davis Dr Ste 220, Durham, North Caroli...Phone Number
(984) 884-6030Website
www.opusgtx.comRevenue
$12 MillionStock Symbol
IRDIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company in the biotechnology and ophthalmology industry, focused on developing innovative gene therapies for inherited retinal diseases and other retinal and refractive disorders. Headquartered in the United States, the company conducts research and development in ophthalmic gene therapies and is dedicated to creating treatments that correct or compensate for genetic defects causing retinal degeneration. Opus Genetics aims to deliver durable, vision-preserving and vision-restoring therapies, translating scientific breakthroughs into safe and effective solutions for patients with rare and common retinal conditions, while striving to lead global innovation in ophthalmic gene therapy.Explore more
Opus Genetics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Opus Genetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Opus Genetics recently announced quarterly report
Product Launch: Get notified when Opus Genetics launches new products
Opus Genetics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Opus Genetics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Opus Genetics
Check out if Opus Genetics is spiking on competitors!
Click to see if Opus Genetics had a recent Job posting/layoffs
Check if Opus Genetics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Opus Genetics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Opus Genetics
Compare insights from companies similar to Opus Genetics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Opus Genetics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Opus Genetics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Opus Genetics.
Opus Genetics financials insights
Gather financial insights about Opus Genetics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$4.5M
2026
Stock/Share Issuance
$159.9M
Opus Genetics Tech Stack
A closer look at the technologies used by Opus Genetics
Most Recent Scoops
Project
Opus Genetics has dosed the first patient in a phase I/II trial of MDX-2003, a tetraspecific T-cell engager targeting CD19 and CD20, for relapsed/refractory lymphoma, designed to address resistance mechanisms seen with CD20-only bispecific therapies.
Clinical Operations
Partnership
Opus Genetics has entered into a commercial partnership with Viatris for the commercial rights to its presbyopia eye drop asset, with a PDUFA date in October, entitling Opus Genetics to approximately $100 million in milestones and a double-digit royalty tiering into the 20s.
Partnership, Pharmaceuticals
Project
Opus Genetics has reported early efficacy signals from the first patient treated in its BEST1 gene therapy trial a 63-year-old with the recessive form of the disease who demonstrated an improvement of 12 letters of vision over three months, with resolution of subretinal fluid in the foveal area following treatment, with results from the remaining four patients expected in September.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Opus Genetics has treated six patients three adults and three adolescents in its LCA5 gene therapy trial, with the University of Pennsylvania describing the results at the recent ARVO conference as normalization of cone photoreceptor sensitivity, with adults having 18 months of follow-up data and children having 6 months of data.
Medical Research, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Opus Genetics News & Media
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseOpus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 ResultsOpus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseOpus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Opus Genetics
Sign Up For FreeTo access detailed company insights
Opus Genetics is a clinical-stage biopharmaceutical company in the biotechnology and ophthalmology industry, focused on developing innovative gene therapies for inherited retinal diseases and other retinal and refractive disorders. Headquartered in the United States, the company conducts research and development in ophthalmic gene therapies and is... Read More
